177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians

177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians

Purpose: There is increasing evidence for convincing efficacy and safety of 177Lu-labled prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) for metastatic castration-resistant prostate cancer (mCRPC). However, data are not available regarding the feasibility of 177Lu-lable...

Full description

Bibliographic Details
Main Authors: Ai, S. (Author), Bu, T. (Author), Guo, H. (Author), Jia, R. (Author), Meng, Q. (Author), Ni, Y. (Author), Qiu, X. (Author), Shao, G. (Author), Shi, L. (Author), Wang, F. (Author), Wu, W. (Author), Yao, X. (Author), Yu, F. (Author), Zang, S. (Author), Zhang, L. (Author), Zhang, P. (Author)
Format: Article
Language:English
Published: Frontiers Media S.A. 2022
Subjects:
177Lu
metastatic castration-resistant prostate cancer (mCRPC)
prostate cancer
prostate-specific membrane antigen (PSMA)
radioligand therapy (RLT)
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items